Teva introduces generic Provigil

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Mar 31 2012Teva

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces the launch of the authorized generic of Provigil® (modafinil). Provigil® is marketed by Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. This product will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has commenced.

The brand product had annual sales of approximately $1.1 billion in the United States, based on IMS sales data.

Source:

Teva

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Common HIV drugs linked to reduced Alzheimer's disease risk
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
LabVantage celebrates customer success with record number of software deployments in FY 2024
Lancet Commission predicts sharp increase in global prostate cancer cases
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
Study highlights global fertility decline and its implications for the future
Supply chain assessment and management, optimizing pharmaceutical supply chains

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals